Compare Enveric Biosciences Inc (ENVB) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Revvity Inc — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Revvity Inc trades at $111.3 (market cap $12.42B). The key difference: Revvity Inc is far larger — about 2334.6× Enveric Biosciences Inc's market cap, and Revvity Inc pays a 0.25% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | RVTY | |
|---|---|---|
Market Cap | $5.32M | $12.42B |
Sector | Health | Technology |
52-Week High | $17.40 | $117.75 |
52-Week Low | $1.28 | $82.26 |
Enterprise Value | $408.82K | $14.91B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
RVTY trades at $111.40, up 0.17% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company maintains stable revenue around $2.9B with an 8.26% net income margin, though its P/E ratio of 53.53 suggests premium valuation. Recent news highlights AI integration advances and FDA clearances, supporting growth initiatives.
Outlook is cautiously optimistic with strong analyst buy ratings (51.72%) and a $111.43 consensus target, but high valuation and margin pressures pose risks. Earnings on August 4, 2026, will be critical for confirming growth trajectory amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
